User login
NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.
NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.
NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.